Literature DB >> 31591051

Screening for differentiated thyroid cancer in selected populations.

Livia Lamartina1, Giorgio Grani2, Cosimo Durante2, Sebastiano Filetti2, David S Cooper3.   

Abstract

The main purpose of cancer screening programmes should not be to detect all cancers, but to discover potentially fatal or clinically relevant cancers. The US Preventive Services Task Force recommends against screening for thyroid cancer in the general, asymptomatic adult population, as such screening would result in harms that outweigh any potential benefits. This recommendation does not apply to patients with symptoms or to individuals at increased risk of thyroid cancer because of a history of exposure to ionising radiation (in childhood, as radioactive fallout, or in medical treatment as low-dose radiotherapy for benign conditions or high-dose radiation for malignancy), inherited genetic syndromes associated with thyroid cancer (eg, familial adenomatous polyposis), or one or more first-degree relatives with a history of thyroid cancer. We discuss the evidence for and against screening individuals who are at high risk, and consider the different screening tools available.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2019        PMID: 31591051     DOI: 10.1016/S2213-8587(19)30324-9

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  15 in total

Review 1.  An update on familial nonmedullary thyroid cancer.

Authors:  Sabrine A Ammar; Wilson M Alobuia; Electron Kebebew
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

2.  Epidemiology of Thyroid Cancer.

Authors:  Cari M Kitahara; Arthur B Schneider
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-07-01       Impact factor: 4.090

3.  The Effect of Gout on Thyroid Cancer Incidence: A Nested Case-Control Study Using a National Health Screening Cohort.

Authors:  So Young Kim; Dae Myoung Yoo; Mi Jung Kwon; Ji Hee Kim; Joo-Hee Kim; Woo Jin Bang; Sung Kyun Kim; Hyo Geun Choi
Journal:  J Pers Med       Date:  2022-05-27

Review 4.  Small molecule inhibitors targeting the cancers.

Authors:  Gui-Hong Liu; Tao Chen; Xin Zhang; Xue-Lei Ma; Hua-Shan Shi
Journal:  MedComm (2020)       Date:  2022-10-13

5.  Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.

Authors:  Jingan Zhou; Preeti Singh; Kanhua Yin; Jin Wang; Yujia Bao; Menghua Wu; Kush Pathak; Sophia K McKinley; Danielle Braun; Carrie C Lubitz; Kevin S Hughes
Journal:  Ann Surg Oncol       Date:  2021-03-03       Impact factor: 5.344

6.  Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer.

Authors:  Shuang Yu; Changan Liu; Yingtong Hou; Jie Li; Zhuming Guo; Xinwen Chen; Luyao Zhang; Sui Peng; Shubin Hong; Lixia Xu; Xiaoxing Li; Rengyun Liu; Shuwei Chen; Bin Li; Zongpeng Weng; Yanbing Li; Weiming Lv; Jun Yu; Haipeng Xiao
Journal:  Oncogene       Date:  2022-03-12       Impact factor: 9.867

Review 7.  Contemporary Thyroid Nodule Evaluation and Management.

Authors:  Giorgio Grani; Marialuisa Sponziello; Valeria Pecce; Valeria Ramundo; Cosimo Durante
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

8.  Integrated analysis of RNA-binding proteins in thyroid cancer.

Authors:  Jing Zhen; Zhe Song; WenJie Su; Qing-Cui Zeng; JiaCen Li; Qin Sun
Journal:  PLoS One       Date:  2021-03-12       Impact factor: 3.240

9.  Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case.

Authors:  Tian Yang; Longsheng Huang; Chang Chen; Han Luo; Yong Jiang
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

10.  CHEK2 mutations and papillary thyroid cancer: correlation or coincidence?

Authors:  Kortbeek Koen; De Putter Robin; Naert Eline
Journal:  Hered Cancer Clin Pract       Date:  2022-01-31       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.